Europe Gene Expression Market Report and Forecast 2024-2032

Europe Gene Expression Market Analysis

Gene expression enables any specific part of DNA to contribute to the basic functionality of different cells in the human body including nerve cells and neurons in the brain. It is a fundamental aspect of gene therapies as it includes procedures like altering or silencing genes within a patient's cells to treat or prevent disease.

In February 2024, Vertex Pharmaceuticals and CRISPR Therapeutics received regulatory approval for Casgevy (exagamglogene autotemcel) after receiving conditional marketing authorisation for gene therapy from the European Commission. The CRISPR treatment is the first gene therapy approved in Europe for sickle cell disease and transfusion-dependent beta-thalassemia (TDT).  The approval of Casgevy for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia (TDT) represents a significant development, propelling the Europe gene expression market growth.

United Kingdom’s market share is poised to witness a notable upswing in the forecast period. The growth can be attributed to its increasing expenditure on conducting more clinical trials in cell and gene therapy. United Kingdom is the leading destination for cell and gene therapy clinical trials, with 84 drugs in clinical development as of October 2023, followed by France (45), Spain (44), and Germany (40).  Europe gene expression market demand is further fuelled by abundance of innovations in bioscience and healthcare. Despite experiencing significant lows in the past, market players have significantly gained hefty investments as venture capital (VC) funding. Notably, half of the VC funding has been secured by European cell and gene therapy companies in 2023 contributing to the expansion of market share.

With increasing preference for personalised medicine, gene expression is finding its application in treatment of several chronic diseases, including cancer. This is one of the major Europe gene expression market trends. In January 2024, researchers from the Wellcome Sanger Institute conducted an analysis of 370 candidate priority drugs across various cancer types including lung, ovarian and breast candidates. With gene expression analysis, the comprehension of the functional and genomic information of cancer cells becomes feasible contributing to the development of more effective cancer treatments. Such advancements in cancer research and therapy development with gene expression are likely to significantly impact the gene expression market in Europe and globally.

Europe Gene Expression Market Report Snapshots

Europe Gene Expression Market Size

Europe Gene Expression Market Analysis

Europe Gene Expression Companies